Skip to main content
    P

    Protalix Biotherapeutics Inc (PLX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $3.02
    -0.03 (-0.98%)

    Market Cap: $257.17M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Protalix Biotherapeutics Inc (PLX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 10, 2026. Financial statements from company filings, amounts in US dollars.

    Protalix Biotherapeutics reported revenue of $52.74M for the fiscal year ended Dec 31, 2025, down 1.2% from the year before. That year, net income was -$6.60M with a net margin of -12.5%, operating cash flow was -$11.99M and free cash flow was -$13.63M. The quarter ended Sep 30, 2026 had revenue of $21.93M and net income of $3.96M.

    Revenue and Margins

    The operating margin was -10.4% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $9.20M, a compound annual rate of 21.4%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$52.74M-1.2%48.8%-10.4%-12.5%
    Dec 2024$53.40M-18.5%54.5%7.3%5.5%
    Dec 2023$65.49M+37.5%64.9%16.0%12.7%
    Dec 2022$47.64M+24.2%58.9%-27.3%-31.3%
    Dec 2021$38.35M-39.0%57.4%-53.4%-71.9%
    Dec 2020$62.90M+15.0%82.7%4.3%-10.4%
    Dec 2019$54.69MN/A80.1%-19.6%-33.4%
    Dec 2018$0-100.0%N/AN/AN/A
    Dec 2017$21.08M+129.1%27.7%-163.8%-395.9%
    Dec 2016$9.20MN/A8.7%-360.5%-319.2%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the company posted a net loss after a profit the year before. In the quarter ended Sep 2026, net income rose 68.5% from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$52.74M$53.40M$65.49M$47.64M$38.35M$62.90M$54.69M$0$21.08M$9.20M
    Cost of revenue$26.99M$24.32M$22.98M$19.59M$16.35M$10.87M$10.89M$9.30M$15.23M$8.40M
    Gross profit$25.75M$29.08M$42.51M$28.05M$22.00M$52.02M$43.80M-$9.30M$5.85M$801.00K
    Research and development$19.57M$12.97M$17.09M$29.35M$29.73M$38.17M$44.62M$33.33M$32.17M$30.41M
    Operating income-$5.50M$3.92M$10.46M-$13.01M-$20.46M$2.71M-$10.72M-$19.31M-$34.52M-$33.16M
    Net income-$6.60M$2.93M$8.31M-$14.93M-$27.58M-$6.52M-$18.28M-$26.46M-$83.44M-$29.36M
    EBITDA-$4.14M$5.46MN/A-$13.01MN/AN/AN/AN/AN/AN/A
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$21.93M$19.90M$33.75M$9.12M$17.85M$15.66M$10.11M$18.22M$17.96M$13.47M$3.75M$10.49M
    Gross profit$14.05M$12.13M$29.62M$4.50M$9.53M$9.79M$1.93M$14.33M$9.58M$4.02M$1.15M$1.63M
    Operating income$4.05M$4.67M$21.15M-$4.66M$2.13M$1.17M-$4.14M$7.21M$3.99M-$2.43M-$4.86M-$5.62M
    Net income$3.96M$3.78M$18.32M-$5.50M$2.35M$164.00K-$3.62M$6.49M$3.24M-$2.20M-$4.59M-$6.04M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $1.38M by $13.30M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$82.35M$73.42M$84.43M$55.79M$73.67M$67.93M$45.39M$61.13M$72.21M$82.25M
    Current assets$66.67M$60.08M$69.93M$44.88M$61.67M$55.72M$32.48M$52.98M$62.65M$71.87M
    Cash and equivalents$14.68M$19.76M$23.63M$17.11M$38.98M$18.27M$17.79M$37.81M$51.16M$63.28M
    Total liabilities$34.12M$30.21M$50.87M$66.43M$79.70M$94.97M$115.71M$114.01M$101.67M$92.20M
    Short-term debt$1.38M$1.50M$20.25M$0$1.21M$58.51M$4.30M$0$5.92M$53.87M
    Long-term debtN/AN/AN/A$28.19M$27.89M$0$50.96M$47.97M$46.27M$19.34M
    Shareholder equity$48.23M$43.21M$33.57M-$10.64M-$6.04M-$27.04M-$70.32M-$52.88M-$29.46M-$9.96M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$118.24M$110.34M$102.34M$82.35M$82.26M$78.49M$73.89M$73.42M$61.56M$91.54M$89.83M$84.43M
    Total liabilities$37.69M$38.93M$35.11M$34.12M$29.36M$28.58M$28.68M$30.21M$29.13M$62.96M$60.04M$50.87M
    Cash and equivalents$22.04M$27.42M$41.00M$14.68M$13.65M$17.89M$19.46M$19.76M$27.41M$23.40M$27.21M$23.63M
    Shareholder equity$80.55M$71.40M$67.23M$48.23M$52.91M$49.90M$45.21M$43.21M$32.44M$28.58M$29.79M$33.57M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$11.99M$8.67M-$1.32M-$25.00M-$10.29M-$26.11M-$19.36M-$7.74M-$9.99M-$32.10M
    Capital expenditures$1.64M$1.28M$1.15M$628.00K$1.46M$655.00K$627.00K$686.00K$971.00K$849.00K
    Free cash flow-$13.63M$7.39M-$2.47M-$25.63M-$11.74M-$26.76M-$19.98M-$8.43M-$10.96M-$32.95M
    Investing cash flow-$2.37M$4.22M-$16.71M-$5.04M$18.92M-$19.95M-$883.00K-$591.00K-$1.12M-$967.00K
    Financing cash flow$9.33M-$16.79M$24.67M$8.24M$12.08M$46.47M$0-$4.75M-$1.42M$19.70M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$3.90M-$10.40M$22.02M$2.03M-$3.73M-$5.23M-$5.06M$3.99M$4.11M-$3.61M$4.19M$3.60M
    Capital expenditures$737.00K$593.00K$761.00K$403.00K$498.00K$431.00K$306.00K$425.00K$87.00K$172.00K$598.00K$250.00K
    Free cash flow$3.17M-$10.99M$21.26M$1.63M-$4.23M-$5.66M-$5.36M$3.57M$4.02M-$3.78M$3.59M$3.35M
    Last 12 quarters

    Frequently Asked Questions About PLX

    What is Protalix Biotherapeutics' annual revenue?

    Protalix Biotherapeutics reported revenue of $52.74M for the fiscal year ended Dec 31, 2025.

    How fast is Protalix Biotherapeutics' revenue growing?

    Revenue was down 1.2% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 3.5%.

    Is Protalix Biotherapeutics profitable?

    No. Protalix Biotherapeutics reported net income of -$6.60M for the fiscal year ended Dec 31, 2025, with a net margin of -12.5%.

    How much free cash flow does PLX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$11.99M minus capital expenditures of $1.64M produced free cash flow of -$13.63M.

    How much debt does Protalix Biotherapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $1.38M and cash and equivalents of $14.68M.